Financial News

Geron Delays Stem Cell Trial

Awaiting an FDA review, Geron Corp. (Nasdaq: GERN) delayed a trial of an embryonic stem cell treatment for spinal cord injury sending the stock price tumbling 75 cents to $6.48.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback